<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">ANG</journal-id>
<journal-id journal-id-type="hwp">spang</journal-id>
<journal-id journal-id-type="nlm-ta">Angiology</journal-id>
<journal-title>Angiology</journal-title>
<issn pub-type="ppub">0003-3197</issn>
<issn pub-type="epub">1940-1574</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage CA: Los Angeles, CA</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/0003319711408587</article-id>
<article-id pub-id-type="publisher-id">10.1177_0003319711408587</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Coronary Heart Disease</subject>
</subj-group>
</article-categories>
<title-group><article-title>Adiponectin and sE-selectin Concentrations in Relation to Inflammation in Obese Type 2 Diabetic Patients With Coronary Heart Disease</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>El-Mesallamy</surname>
<given-names>Hala O.</given-names>
</name>
<degrees>PhD</degrees>
<xref ref-type="aff" rid="aff1-0003319711408587">1</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Hamdy</surname>
<given-names>Nadia M.</given-names>
</name>
<degrees>PhD</degrees>
<xref ref-type="aff" rid="aff1-0003319711408587">1</xref>
<xref ref-type="corresp" rid="corresp1-0003319711408587"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Salman</surname>
<given-names>Tarek M.</given-names>
</name>
<degrees>PhD</degrees>
<xref ref-type="aff" rid="aff2-0003319711408587">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Ibrahim</surname>
<given-names>Sherine M.</given-names>
</name>
<degrees>B.Pharm Sc.</degrees>
<xref ref-type="aff" rid="aff3-0003319711408587">3</xref>
</contrib>
</contrib-group>
<aff id="aff1-0003319711408587"><label>1</label>Biochemistry Department, Faculty of Pharmacy, Ain Shams University, Cairo, Egypt</aff>
<aff id="aff2-0003319711408587"><label>2</label>Biochemistry Department, Faculty of Pharmacy, AL-Azhar University, Cairo, Egypt</aff>
<aff id="aff3-0003319711408587"><label>3</label>Biochemistry Department, Faculty of Pharmacy, modern Sciences and Arts University, Cairo, Egypt</aff>
<author-notes>
<corresp id="corresp1-0003319711408587">Nadia M. Hamdy, Faculty of Pharmacy, Ain Shams University, Abassia, 11566, Cairo, Egypt Email: <email>nadia_hamdy@hotmail.com</email>
</corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>2</month>
<year>2012</year>
</pub-date>
<volume>63</volume>
<issue>2</issue>
<fpage>96</fpage>
<lpage>102</lpage>
<permissions>
<copyright-statement>© SAGE Publications 2012</copyright-statement>
<copyright-year>2012</copyright-year>
<copyright-holder content-type="sage">SAGE Publications</copyright-holder>
</permissions>
<abstract>
<p>Adipose tissue can release proinflammatory mediators, namely C-reactive protein (CRP), interleukin 1β (IL-1β), and monocyte chemotactic protein 1 (MCP-1), contributing to vascular injury and insulin resistance (IR). Other mediators namely, adiponectin and nitric oxide (NO) are protective. We enrolled type 2 diabetes mellitus (T2DM) obese male patients without coronary heart disease ([CHD] group II, n = 25) and T2DM obese patients with CHD (group III, n = 25). They were compared with 20 age- and body mass index (BMI)-matched nondiabetic control males (group I). Fasting blood glucose (FBG), glycated hemoglobin (HbA<sub>1c</sub>%), lipids, insulin, malondialdehyde ([MDA]; lipid peroxidation product), NO, high-sensitivity CRP (hsCRP), IL-1β, MCP-1, adiponectin as well as sE-selectin concentration were significantly different in patients with T2DM and CHD compared with patients without CHD and nondiabetic controls (<italic>P</italic> = .01). There was a significant negative correlation between adiponectin and E-selectin (<italic>P</italic> = .0001). Adipose tissue in T2DM obese patients may contribute to the pathogenesis of CHD.</p>
</abstract>
<kwd-group>
<kwd>Obesity</kwd>
<kwd>type 2 diabetes mellitus</kwd>
<kwd>coronary heart diseases</kwd>
<kwd>adiponectin</kwd>
<kwd>sE-selectin</kwd>
<kwd>interleukin 1β</kwd>
<kwd>monocyte chemotactic protein 1</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="section1-0003319711408587">
<title>Introduction</title>
<p>One third of the world’s population is at risk of coronary heart diseases (CHDs) due to being overweight or obese.<sup><xref ref-type="bibr" rid="bibr1-0003319711408587">1</xref></sup> Obesity is characterized by an excess of adipose tissue components of adipogenesis including adiponectin.<sup><xref ref-type="bibr" rid="bibr2-0003319711408587">2</xref></sup> Adiponectin is a 30-kDa protein synthesized predominantly by white adipose tissue (WAT).<sup><xref ref-type="bibr" rid="bibr3-0003319711408587">3</xref></sup> In recent years, a function of adiponectin was associated mainly with insulin resistance (IR). Also, adiponectin function is connected with lipid metabolism and dyslipidemia.<sup><xref ref-type="bibr" rid="bibr4-0003319711408587">4</xref></sup> It was shown that adiponectin is negatively related to high-density lipoprotein cholesterol (HDL-C) and positively to triacylglycerol (TAG) concentration.<sup><xref ref-type="bibr" rid="bibr5-0003319711408587">5</xref></sup> Low adiponectin concentration was observed in obesity,<sup><xref ref-type="bibr" rid="bibr3-0003319711408587">3</xref></sup> type 2 diabetes mellitus (T2DM),<sup><xref ref-type="bibr" rid="bibr6-0003319711408587">6</xref></sup> CHD,<sup><xref ref-type="bibr" rid="bibr7-0003319711408587">7</xref></sup> and in hypertension (HTN).<sup><xref ref-type="bibr" rid="bibr8-0003319711408587">8</xref></sup> Adiponectin may inhibit atherogenesis by influencing proinflammatory cytokine secretion and by inhibiting the endothelial expression of adhesion molecules.<sup><xref ref-type="bibr" rid="bibr9-0003319711408587">9</xref></sup></p>
<p>Epidemiological studies showed that CHD is the main cause of premature mortality among T2DM patients.<sup><xref ref-type="bibr" rid="bibr10-0003319711408587">10</xref></sup> Type 2 DM is associated with accelerated atherogenesis and is considered an independent risk factor for CHD.<sup><xref ref-type="bibr" rid="bibr11-0003319711408587">11</xref></sup> Our previous studies indicated that in T2DM patients, with or without CHD, the concentration of soluble intercellular adhesion molecule 1 (sICAM-1) was significantly increased and correlated with concentration of proinflammatory cytokines, high-sensitivity C-reactive protein (hsCRP) as well as platelet-selectin (P-selectin)<sup><xref ref-type="bibr" rid="bibr12-0003319711408587">12</xref></sup>; moreover, P-selectin was significantly increased and correlated with hsCRP and interleukin 1β (IL-1β).<sup><xref ref-type="bibr" rid="bibr13-0003319711408587">13</xref></sup></p>
<p>We evaluated the role of adiponectin in male obese T2DM patients with and without CHD. We also estimated the relationship between adiponectin, sE-selectin, hsCRP, IL-1β, and monocyte chemotactic protein 1 (MCP-1) levels as well as selected anthropometric, biochemical, and clinical parameters.</p>
</sec>
<sec id="section2-0003319711408587">
<title>Participants and Methods</title>
<sec id="section3-0003319711408587">
<title>Study Participants</title>
<p>A total of 70 male participants were included in the study, 20 of which served as nondiabetic healthy obese controls (group I). The definition of a nondiabetic is a participant who has a fasting blood glucose (FBG) level lower than 110 mg/dL. None of the healthy controls were taking any medication or dietary supplements. Fifty patients enrolled in this study were classified into the following groups: 25 T2DM obese participants without CHD (group II) who were selected from patients attending the Endocrinology Department of Ain Shams University Specialized Hospitals (ASUSH) and 25 T2DM obese participants with CHD (group III) admitted to the Intensive Care Unit, Cardiology Department, ASUSH. A patient was considered to have CHD if he had a history of myocardial infarction (MI) or the diagnosis was based on the result of coronary angiography. The following clinical information was obtained from all participants: current medication consumption, presence of macrovascular disease, and family history. The medication regimen included statins, angiotensin-converting enzyme inhibitors, and antiplatelet agents (see <xref ref-type="table" rid="table1-0003319711408587">Table 1</xref>). It is important to emphasize that group II received the same medication as group III for dyslipidemia.</p>
<table-wrap id="table1-0003319711408587" position="float">
<label>Table 1.</label>
<caption>
<p>Clinical and Hemodynamic Characteristics of Participants Evaluated<sup><xref ref-type="table-fn" rid="table-fn2-0003319711408587">a</xref></sup></p>
</caption>
<graphic alternate-form-of="table1-0003319711408587" xlink:href="10.1177_0003319711408587-table1.tif"/>
<table>
<thead>
<tr>
<th>
</th>
<th>
</th>
<th align="center" colspan="2">T2DM</th>
<th>
</th>
</tr>
<tr>
<th>Groups</th>
<th align="center">Nondiabetic Obese Control</th>
<th align="center">Without MI</th>
<th align="center">With MI</th>
<th>
<italic>P</italic><sup><xref ref-type="table-fn" rid="table-fn4-0003319711408587">d</xref></sup>
</th>
</tr>
</thead>
<tbody>
<tr>
<td>n</td>
<td>20</td>
<td>25</td>
<td>25</td>
<td>
</td>
</tr>
<tr>
<td>Age (years)</td>
<td>38.5 ± 4 (36-46)</td>
<td>42 ± 3 (36-46)</td>
<td>40.5 ± 3 (36-46)</td>
<td>NS</td>
</tr>
<tr>
<td>HTN</td>
<td>Non</td>
<td>6 (24%)</td>
<td>25 (100%)</td>
<td>
</td>
</tr>
<tr>
<td>Smoking</td>
<td>Non</td>
<td>5 (20%)</td>
<td>6 (24%)</td>
<td>
</td>
</tr>
<tr>
<td>BMI (kg/m<sup>2</sup>)</td>
<td>31 ± 1.2 (30-34)</td>
<td>32 ± 1.4(30-34)</td>
<td>31.5 ± 0.2(30-34)</td>
<td>NS</td>
</tr>
<tr>
<td>FBG (mg/dL)</td>
<td>103 ± 3 (93-105)</td>
<td>279 ± 27<sup><xref ref-type="table-fn" rid="table-fn2-0003319711408587">b</xref></sup> (227-340)</td>
<td>283 ± 18<sup><xref ref-type="table-fn" rid="table-fn2-0003319711408587">b</xref></sup> (349-319)</td>
<td>.01</td>
</tr>
<tr>
<td>HbA<sub>1c</sub> %</td>
<td>4.5 ± 0.6 (4-5.5)</td>
<td>13 ± 1.4<sup><xref ref-type="table-fn" rid="table-fn2-0003319711408587">b</xref></sup> (11-16)</td>
<td>13 ± 1.1<sup><xref ref-type="table-fn" rid="table-fn2-0003319711408587">b</xref></sup> (11-15)</td>
<td>.01</td>
</tr>
<tr>
<td>T2DM duration (years)</td>
<td align="center">------</td>
<td>3.3 ± 1 (2-5)</td>
<td>4.4 ±1 (2-5)</td>
<td>
</td>
</tr>
<tr>
<td>Medication</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
</tr>
<tr>
<td>ACEI</td>
<td>Non</td>
<td>50 %</td>
<td>85%</td>
<td>
</td>
</tr>
<tr>
<td>Statins</td>
<td>Non</td>
<td>100 %</td>
<td>100%</td>
<td>
</td>
</tr>
<tr>
<td>Anticoagulants</td>
<td>Non</td>
<td>65 %</td>
<td>75 %</td>
<td>
</td>
</tr>
<tr>
<td>Insulin (µIU/mL)</td>
<td>8 ± 1.3 (6-9)</td>
<td>101 ± 17<sup><xref ref-type="table-fn" rid="table-fn2-0003319711408587">b</xref></sup> (79-129)</td>
<td>109 ± 7<sup><xref ref-type="table-fn" rid="table-fn2-0003319711408587">b</xref></sup> (85-121)</td>
<td>.01</td>
</tr>
<tr>
<td>HOMA-IR index</td>
<td>2 ± 0.3 (1.5-2.5)</td>
<td>70 ± 14<sup><xref ref-type="table-fn" rid="table-fn2-0003319711408587">b</xref></sup> (48-99)</td>
<td>76 ± 8<sup><xref ref-type="table-fn" rid="table-fn2-0003319711408587">b</xref></sup> (62-90)</td>
<td>.01</td>
</tr>
<tr>
<td>TAG (mg/dL)</td>
<td>116 ± 25 (87-169)</td>
<td>277 ± 21<sup><xref ref-type="table-fn" rid="table-fn2-0003319711408587">b</xref></sup> (245-346)</td>
<td>284 ± 20<sup><xref ref-type="table-fn" rid="table-fn2-0003319711408587">b</xref></sup> (247-339)</td>
<td>.01</td>
</tr>
<tr>
<td>TC (mg/dL)</td>
<td>177 ± 16 (148-200)</td>
<td>305 ± 44<sup><xref ref-type="table-fn" rid="table-fn2-0003319711408587">b</xref></sup> (245-370)</td>
<td>285 ± 23<sup><xref ref-type="table-fn" rid="table-fn2-0003319711408587">b</xref>,<xref ref-type="table-fn" rid="table-fn3-0003319711408587">c</xref></sup> (245-365)</td>
<td>.01</td>
</tr>
<tr>
<td>HDL-C (mg/dL)</td>
<td>39 ± 2 (36-41)</td>
<td>25 ± 2<sup><xref ref-type="table-fn" rid="table-fn2-0003319711408587">b</xref></sup> (22-29)</td>
<td>27 ± 2<sup><xref ref-type="table-fn" rid="table-fn2-0003319711408587">b</xref>,<xref ref-type="table-fn" rid="table-fn3-0003319711408587">c</xref></sup> (22-29)</td>
<td>.01</td>
</tr>
<tr>
<td>LDL-C (mg/dL)</td>
<td>118 ± 20 (81-165)</td>
<td>266 ± 22<sup><xref ref-type="table-fn" rid="table-fn2-0003319711408587">b</xref></sup> (230-300)</td>
<td>287 ± 14<sup><xref ref-type="table-fn" rid="table-fn2-0003319711408587">b</xref>,<xref ref-type="table-fn" rid="table-fn3-0003319711408587">c</xref></sup> (250-312)</td>
<td>.01</td>
</tr>
<tr>
<td>TC/HDL-C</td>
<td>4.5 ± 0.4 (4-5)</td>
<td>12 ± 2<sup><xref ref-type="table-fn" rid="table-fn2-0003319711408587">b</xref></sup> (9-16.5)</td>
<td>10.4 ± 1.2<sup><xref ref-type="table-fn" rid="table-fn2-0003319711408587">b</xref>,<xref ref-type="table-fn" rid="table-fn3-0003319711408587">c</xref></sup> (9-13)</td>
<td>.01</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn1-0003319711408587">
<p>Abbreviations: T2DM, type 2 diabetes mellitus; MI, myocardial infarction; BMI, body mass index; FBG, fasting blood glucose; HbA<sub>1c</sub>%: glycated hemoglobin; TAG, triacylglycerol; TC, total cholesterol; HDL, high-density lipoprotein; LDL, low-density lipoprotein; NS, not significant.</p>
</fn>
<fn id="table-fn2-0003319711408587">
<p>
<sup>a</sup> Data are given as mean ± SD (range).</p>
</fn>
<fn id="table-fn3-0003319711408587">
<p>
<sup>b,c</sup> Significant difference from nondiabetic obese control and T2DM without MI groups, respectively.</p>
</fn>
<fn id="table-fn4-0003319711408587">
<p><sup>d</sup> <italic>P</italic> values are for the comparison between the control and the study groups.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<p>The study was approved by the Committee on Medical Ethics of ASUSH. The study was carried out in accordance with the regulations and recommendations of the Declaration of Helsinki. All participants gave their written informed consent prior to participation. A detailed medical history and drug treatments were collected for all participants. The exclusion criteria were as follows: age less than 30 or more than 50 years, female gender, T1DM, insulin treatment, renal or hepatic disease, not having acute or chronic inflammatory diseases, and not recently receiving any anti-inflammatory drugs, retinopathy, alcohol or drug abuse, cancer, any hematologic disorder (assessed by complete blood count for every participant), and smoking. The selected T2DM patients didn’t have long duration (see <xref ref-type="table" rid="table1-0003319711408587">Table 1</xref>) to help avoid the presence of diabetic complications, namely retinopathy, neuropathy, and nephropathy, which were further confirmed by physical examination and laboratory investigations. Body mass index (BMI) was calculated as an index of the weight in kg divided by the square of the height in m.</p>
</sec>
<sec id="section4-0003319711408587">
<title>Routine Laboratory Tests</title>
<p>Blood samples were taken from participants after an overnight fast and divided into 2 parts: one containing Na<sub>2</sub>-EDTA (final concentration 1 mg/mL) for glycated hemoglobulin (HbA<sub>1c</sub>%) determination (Stanbio glycohemoglobin, Boerne, TX).<sup><xref ref-type="bibr" rid="bibr14-0003319711408587">14</xref></sup> From the other part sera was obtained, separated, and aliquoted first for the measurement of FBG<sup><xref ref-type="bibr" rid="bibr15-0003319711408587">15</xref></sup> and lipids (total cholesterol [TC]<sup><xref ref-type="bibr" rid="bibr16-0003319711408587">16</xref></sup> and TAG<sup><xref ref-type="bibr" rid="bibr17-0003319711408587">17</xref></sup>) using standard enzymatic techniques. High-density lipoprotein cholesterol was determined after precipitation of apolipoprotein B-containing lipoproteins<sup><xref ref-type="bibr" rid="bibr18-0003319711408587">18</xref></sup> and low-density lipoprotein cholesterol (LDL-C) was determined according to the method of Hatch and Lees.<sup><xref ref-type="bibr" rid="bibr19-0003319711408587">19</xref></sup></p>
<p>Oxidative susceptibility of LDL-C was measured as the level of MDA.<sup><xref ref-type="bibr" rid="bibr20-0003319711408587">20</xref></sup> Insulin sensitivity was assessed by indirect Homeostasis Model Assessment–Insulin Resistance (HOMA-IR) index based on FBG and insulin concentration.<sup><xref ref-type="bibr" rid="bibr21-0003319711408587">21</xref></sup> Nitric oxide (NO) was measured according to the method of Green et al.<sup><xref ref-type="bibr" rid="bibr22-0003319711408587">22</xref></sup></p>
</sec>
<sec id="section5-0003319711408587">
<title>Inflammatory Markers Determination</title>
<p>The acute-phase reactant hsCRP as well as cytokines IL-1β and MCP-1 were measured in serum aliquots kept at −70°C using enzyme-linked immunosorbent assay (ELISA) technique, according to the manufacturer’s instructions.</p>
<p>Total adiponectin and soluble E-selectin (sE-selectin) were measured in serum aliquots (stored at −70°C) using an ELISA technique, according to the manufacturer’s instructions (R&amp;D Systems, Wiesbaden, Germany).</p>
</sec>
<sec id="section6-0003319711408587">
<title>Statistical Analysis</title>
<p>Data are presented as mean ± SD (range). Measured parameters levels between groups were compared with a student <italic>t</italic> test. To determine the differences between groups, analysis of variance (ANOVA) followed by Bonferroni post hoc analysis was used for multiple comparisons between different groups. Correlation analyses between adiponectin and sE-selectin levels and other laboratory values or patient characteristics were carried out using Pearson correlation coefficient. For correlation between lipids, inflammatory markers, and the ELISA markers, stepwise linear regression analysis was also used. Significance was set at <italic>P</italic> ≤ .05 (2 tailed). All statistical analyses were performed with SPSS, version 17.0 (SPSS Inc.).</p>
</sec>
</sec>
<sec id="section7-0003319711408587">
<title>Results</title>
<p>The clinical and demographic data of all participants are presented in <xref ref-type="table" rid="table1-0003319711408587">Table 1</xref>, where FBG, HbA<sub>1c</sub>%, insulin, and lipid profile were significantly higher in the diabetic subgroups compared with the control group (<italic>P</italic> &lt; .05). In addition, a significant difference was observed among both diabetic groups, with those of group III showing the highest values.</p>
<p>As indicated in <xref ref-type="table" rid="table2-0003319711408587">Table 2</xref>, the mean ± SD (range) of MDA, hsCRP, IL-1β, MCP-1, and sE-selectin levels were significantly higher in the diabetic subgroups compared with those obtained in the nondiabetic control group (<italic>P</italic> &lt; .05). In addition, a significant difference was observed among both diabetic groups, with those of group III showing the highest values.</p>
<table-wrap id="table2-0003319711408587" position="float">
<label>Table 2.</label>
<caption>
<p>Comparison of NO, MDA, hsCRP, IL-1β, MCP-1, Adiponectin, and sE-selectin in Obese Healthy Controls, T2DM Patients With and Without MI<sup><xref ref-type="table-fn" rid="table-fn6-0003319711408587">a</xref></sup></p>
</caption>
<graphic alternate-form-of="table2-0003319711408587" xlink:href="10.1177_0003319711408587-table2.tif"/>
<table>
<thead>
<tr>
<th rowspan="3">Groups/Parametersn</th>
<th align="center" rowspan="2">Nondiabetic Obese Control</th>
<th align="center" colspan="2">T2DM</th>
<th rowspan="3"><italic>P</italic><sup><xref ref-type="table-fn" rid="table-fn8-0003319711408587">d</xref></sup></th>
</tr>
<tr>
<th align="center">Without MI</th>
<th align="center">With MI</th>
</tr>
<tr>
<th align="center">20</th>
<th align="center">25</th>
<th align="center">25</th>
</tr>
</thead>
<tbody>
<tr>
<td>NO (μmol/L)</td>
<td>40.5 ± 8.5 (25-50)</td>
<td>6 ± 1<sup><xref ref-type="table-fn" rid="table-fn7-0003319711408587">b</xref></sup> (5-8)</td>
<td>6 ± 2<sup><xref ref-type="table-fn" rid="table-fn7-0003319711408587">b</xref></sup> (3.5-8)</td>
<td>.01</td>
</tr>
<tr>
<td>MDA (nmol/mL)</td>
<td>2.75 ± 0.4 (2-3)</td>
<td>6.4 ± 1<sup><xref ref-type="table-fn" rid="table-fn7-0003319711408587">b</xref></sup> (5-7)</td>
<td>6 ± 0.6<sup><xref ref-type="table-fn" rid="table-fn7-0003319711408587">b</xref></sup> (5-7)</td>
<td>.05</td>
</tr>
<tr>
<td>hsCRP (mg/L)</td>
<td>1.7 ± 0.4 (1.2-2.2)</td>
<td>7 ± 1.2<sup><xref ref-type="table-fn" rid="table-fn7-0003319711408587">b</xref></sup> (3.8-8.8)</td>
<td>30.5 ± 5<sup><xref ref-type="table-fn" rid="table-fn7-0003319711408587">b</xref>,<xref ref-type="table-fn" rid="table-fn8-0003319711408587">c</xref></sup> (21-35)</td>
<td>.05</td>
</tr>
<tr>
<td>IL-1β (pg/mL)</td>
<td>20 ± 1.7 (3.8-5.2)</td>
<td>28.4 ± 2.2<sup><xref ref-type="table-fn" rid="table-fn7-0003319711408587">b</xref></sup> (25-32)</td>
<td>28.5 ± 2.5<sup><xref ref-type="table-fn" rid="table-fn7-0003319711408587">b</xref></sup> (25-32)</td>
<td>.05</td>
</tr>
<tr>
<td>MCP-1 (pg/mL)</td>
<td>110.5 ± 7 (97.5-121.5)</td>
<td>124 ± 4<sup><xref ref-type="table-fn" rid="table-fn7-0003319711408587">b</xref></sup> (118-131)</td>
<td>150.5 ± 12.5<sup><xref ref-type="table-fn" rid="table-fn7-0003319711408587">b</xref>,<xref ref-type="table-fn" rid="table-fn8-0003319711408587">c</xref></sup> (133-174)</td>
<td>.05</td>
</tr>
<tr>
<td>Adiponectin (pg/mL)</td>
<td>732 ± 142 (564-1021)</td>
<td>274.5 ± 53.5<sup><xref ref-type="table-fn" rid="table-fn7-0003319711408587">b</xref></sup> (225-447)</td>
<td>253 ± 30<sup><xref ref-type="table-fn" rid="table-fn7-0003319711408587">b</xref></sup> (225-307)</td>
<td>.05</td>
</tr>
<tr>
<td>sE-selectin (ng/mL)</td>
<td>22.3 ± 5 (13.5-27)</td>
<td>35.4 ± 5<sup><xref ref-type="table-fn" rid="table-fn7-0003319711408587">b</xref></sup> (30-53)</td>
<td>40.3 ± 3.3<sup><xref ref-type="table-fn" rid="table-fn7-0003319711408587">b</xref>,<xref ref-type="table-fn" rid="table-fn8-0003319711408587">c</xref></sup> (32-47)</td>
<td>.05</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn5-0003319711408587">
<p>Abbreviations: T2DM, type 2 diabetes mellitus; MI, myocardial infarction; NO, nitric oxide metabolites; MDA, malondialdehyde; hsCRP, high-sensitivity C-reactive protein; IL-1β, interleukin-1β; MCP-1, monocyte chemotactic protein 1; SD, standard deviation.</p>
</fn>
<fn id="table-fn6-0003319711408587">
<p>
<sup>a</sup> Data are presented as mean ± SD (range).</p>
</fn>
<fn id="table-fn7-0003319711408587">
<p>
<sup>b,c</sup> Significant difference from nondiabetic obese control and T2DM without MI groups, respectively.</p>
</fn>
<fn id="table-fn8-0003319711408587">
<p><sup>d</sup> <italic>P</italic> values are for the comparison between the control and the study groups.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<sec id="section8-0003319711408587">
<title>Inflammatory Markers</title>
<p>Regarding MDA levels, there was a significant increase in group II (6.3 ± 0.6 nmol/mL) and group III (6 ± 0.6 nmol/mL) compared with group I (3 ± 1 nmol/mL; <italic>P</italic> &lt; .05). Insulin levels increased 10- and 11-fold in the diabetic groups II and III compared with the healthy controls (<italic>P</italic> &lt; .05). High-sensitivity CRP level was significantly increased in groups II (7 ± 1.2 mg/L) and III (30.5 ± 5 mg/L) compared with the control group (1.7 ± 0.4 mg/L; <italic>P</italic> &lt; .05). Interleukin 1β level in both groups II and III were 28.4 ± 2.2 and 28.5 ± 2.5 pg/mL, respectively; <italic>P</italic> &gt; .05. Regarding the MCP-1 levels, there was a significant increase in group II (124 ± 4.2 ng/mL) and group III (150.5 ± 12.5 ng/mL) compared with group I (110.5 ± 7.4 ng/mL; <italic>P</italic> &lt; .05).</p>
</sec>
<sec id="section9-0003319711408587">
<title>High-Density Lipoprotein Cholesterol and NO</title>
<p>In the diabetic groups II and III, HDL-C and NO levels decreased significantly in comparison with the nondiabetic control group (<italic>P</italic> = .01), however, no difference was observed (<italic>P</italic> &gt; .05) between the 2 diabetic groups.</p>
</sec>
<sec id="section10-0003319711408587">
<title>Adiponectin and sE-selectin</title>
<p>There was a significant decrease in adiponectin levels in groups II (274.5 ± 53.5 pg/mL) and III (253 ± 30 pg/mL) compared with the nondiabetic control group (732 ± 142 pg/mL; <italic>P</italic> &lt; .05). Regarding the sE-selectin level, the elevation in group II was 1.6- and 1.2-fold higher than in groups I and II, respectively.</p>
</sec>
<sec id="section11-0003319711408587">
<title>Correlations</title>
<p>Simple linear regression analysis revealed that in the obese T2DM groups (II and III; n = 50), hyperglycemia, dyslipidemia, hyperinsulinemia, and inflammation (hsCRP, IL-1β, and MCP-1) are correlated to and related to hypoadiponectinemia and endothelial dysfunction (decreased NO and increased sE-selectin level; <xref ref-type="table" rid="table3-0003319711408587">Table 3</xref>). Whereas in multiple linear stepwise regression analysis using either adiponectin or sE-selectin as dependant variable and age, T2DM duration, BMI, FBG, HbA<sub>1c</sub>%, insulin, HOMA-IR, TAG, TC, HDL-C, LDL-C, MDA, NO, hsCRP, IL-1β, and MCP-1 as independent variables, only adiponectin remained significantly associated with and correlated negatively significantly to sE-selectin (<italic>r</italic> = −.642, <italic>P</italic> = .0001; <xref ref-type="fig" rid="fig1-0003319711408587">Figure 1</xref>).</p>
<table-wrap id="table3-0003319711408587" position="float">
<label>Table 3.</label>
<caption>
<p>Linear Regression Analysis Using Either Adiponectin or sE-selectin as Dependent Variable<sup><xref ref-type="table-fn" rid="table-fn10-0003319711408587">a</xref></sup></p>
</caption>
<graphic alternate-form-of="table3-0003319711408587" xlink:href="10.1177_0003319711408587-table3.tif"/>
<table>
<thead>
<tr>
<th>
</th>
<th align="center" colspan="2">Adiponectin</th>
<th align="center" colspan="2">E-selectin</th>
</tr>
<tr>
<th>Variable</th>
<th align="center">β</th>
<th align="center"><italic>P</italic></th>
<th align="center">β</th>
<th align="center"><italic>P</italic></th>
</tr>
</thead>
<tbody>
<tr>
<td>Age</td>
<td>−.235</td>
<td align="center">NS</td>
<td>−.068</td>
<td align="center">NS</td>
</tr>
<tr>
<td>BMI</td>
<td>−.449</td>
<td>.001</td>
<td>.314</td>
<td>.027</td>
</tr>
<tr>
<td>T2DM duration</td>
<td>−.148</td>
<td align="center">NS</td>
<td>.258</td>
<td align="center">NS</td>
</tr>
<tr>
<td>FBG</td>
<td>−.117</td>
<td align="center">NS</td>
<td>.224</td>
<td align="center">NS</td>
</tr>
<tr>
<td>HbA<sub>1c</sub> %</td>
<td>−.634</td>
<td>&lt;.0001</td>
<td>.535</td>
<td>&lt;.0001</td>
</tr>
<tr>
<td>TC</td>
<td>−.079</td>
<td align="center">NS</td>
<td>−.183</td>
<td align="center">NS</td>
</tr>
<tr>
<td>TAG</td>
<td>−.18</td>
<td align="center">NS</td>
<td>.187</td>
<td align="center">NS</td>
</tr>
<tr>
<td>HDL-C</td>
<td>.464</td>
<td>.001</td>
<td>−.229</td>
<td align="center">NS</td>
</tr>
<tr>
<td>LDL-C</td>
<td>−.802</td>
<td>&lt;.0001</td>
<td>.677</td>
<td>&lt;.0001</td>
</tr>
<tr>
<td>TC/HDL-C</td>
<td>−.198</td>
<td align="center">NS</td>
<td>−.014</td>
<td align="center">NS</td>
</tr>
<tr>
<td>LDL-C/HDL-C</td>
<td>−.774</td>
<td>&lt;.0001</td>
<td>.558</td>
<td>&lt;.0001</td>
</tr>
<tr>
<td>Insulin</td>
<td>−.806</td>
<td>&lt;.0001</td>
<td>.689</td>
<td>&lt;.0001</td>
</tr>
<tr>
<td>HOMA-IR</td>
<td>−.714</td>
<td>&lt;.0001</td>
<td>.69</td>
<td>&lt;.0001</td>
</tr>
<tr>
<td>MDA</td>
<td>−.413</td>
<td>.003</td>
<td>.246</td>
<td align="center">NS</td>
</tr>
<tr>
<td align="center">NO</td>
<td>.427</td>
<td>.002</td>
<td>−.222</td>
<td align="center">NS</td>
</tr>
<tr>
<td>hsCRP</td>
<td>−.251</td>
<td align="center">NS</td>
<td>.491</td>
<td>&lt;.0001</td>
</tr>
<tr>
<td>IL-1β</td>
<td>−.431</td>
<td>.002</td>
<td>.51</td>
<td>&lt;.0001</td>
</tr>
<tr>
<td>MCP-1</td>
<td>−.534</td>
<td>&lt;.0001</td>
<td>.714</td>
<td>&lt;.0001</td>
</tr>
<tr>
<td>Adiponectin</td>
<td>
</td>
<td>
</td>
<td>−.642</td>
<td>&lt;.0001</td>
</tr>
<tr>
<td>sE-selectin</td>
<td>−.642</td>
<td>&lt;.0001</td>
<td>
</td>
<td>
</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn9-0003319711408587">
<p>Abbreviations: BMI, body mass index; T2DM, type 2 diabetes mellitus; FBG, fasting blood glucose; HbA<sub>1c</sub>%: glycated hemoglobin; TAG, triacylglycerol; TC, total cholesterol; HDL-C, high-density lipoprotein cholesterol; LDL, low-density lipoprotein cholesterol; NS, not significant; β, standardized coefficients; NS, not significant; HOMA-IR, Homeostasis Model Assessment–Insulin Resistance; NO: nitric oxide metabolites, MDA: malondialdehyde, IL-1β, interleukin 1β; MCP-1, monocyte chemotactic protein 1.</p>
</fn>
<fn id="table-fn10-0003319711408587">
<p>
<sup>a</sup> Evaluated by multiple linear regression models with several levels of adjustment.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<fig id="fig1-0003319711408587" position="float">
<label>Figure 1.</label>
<caption>
<p>Correlation between adiponectin and sE-selectin concentration in studied diabetic groups (n = 50).</p>
</caption>
<graphic xlink:href="10.1177_0003319711408587-fig1.tif"/>
</fig>
</sec>
</sec>
<sec id="section12-0003319711408587">
<title>Discussion</title>
<p>It is widely accepted that obesity is associated with several metabolic disorders including IR and T2DM.<sup><xref ref-type="bibr" rid="bibr23-0003319711408587">23</xref></sup> Moreover, obesity makes it an increasingly important risk factor for CHD and T2DM.<sup><xref ref-type="bibr" rid="bibr24-0003319711408587">24</xref></sup> Coronary heart disease causes most of the excess morbidity and mortality in T2DM.<sup><xref ref-type="bibr" rid="bibr25-0003319711408587">25</xref></sup> The risk factors HTN, dyslipidemia, obesity, IR, hyperinsulinemia, and impaired fibrinolysis cluster in the metabolic syndrome (MetS) create a state of constant and progressive damage to the vascular wall, manifested by a low-grade inflammatory process<sup><xref ref-type="bibr" rid="bibr26-0003319711408587">26</xref></sup> (increased hsCRP, IL-1β, and MCP-1) and endothelial dysfunction (decreased NO and increased sE-selectin). Our results demonstrated an elevated level of MCP-1 and sE-selectin in T2DM patients, where both are considered amplifiers of the inflammatory cascade.<sup><xref ref-type="bibr" rid="bibr27-0003319711408587">27</xref></sup> The mechanisms by which chronic inflammation can evoke T2DM are not clear. However, it is known that adipose tissue can synthesize and release the proinflammatory cytokines; IL-1 and those inflammatory markers are associated with body fat mass. Proinflammatory cytokines and acute phase reactants are involved in multiple metabolic pathways relevant to IR, including insulin regulation, reactive oxygen species, lipoprotein lipase action, and adipocyte function.<sup><xref ref-type="bibr" rid="bibr28-0003319711408587">28</xref></sup> Therefore, activated innate immunity and inflammation are relevant factors in the pathogenesis of T2DM, with our previous data showing that T2DM includes an inflammatory component.<sup><xref ref-type="bibr" rid="bibr12-0003319711408587">12</xref>,<xref ref-type="bibr" rid="bibr13-0003319711408587">13</xref></sup></p>
<p>Nitric oxide is a particularly important endothelium-derived mediator because of its vasodilator and anti-inflammatory properties.<sup><xref ref-type="bibr" rid="bibr29-0003319711408587">29</xref></sup> Thence, in the present study, NO levels decreased significantly in the diabetic groups (II and III). Since NO inhibits leukocyte adhesion and rolling as well as cytokine-induced expression of MCP-1,<sup><xref ref-type="bibr" rid="bibr25-0003319711408587">25</xref></sup> its level was correlated negatively with hyperglycemia, dyslipidemia as well as inflammation. Monocyte chemotactic protein 1 is produced predominantly by macrophages and endothelial cells and is a potent chemotactic factor for monocytes.<sup><xref ref-type="bibr" rid="bibr30-0003319711408587">30</xref></sup> Circulating MCP-1 levels are raised in obese participants, suggesting that the expression of this adipokine is increased in obesity.<sup><xref ref-type="bibr" rid="bibr31-0003319711408587">31</xref></sup></p>
<p>Interleukin 1β mediates cytotoxic effects on pancreatic islets leading to impaired insulin secretion.<sup><xref ref-type="bibr" rid="bibr32-0003319711408587">32</xref></sup> Interleukin 1β correlated with anthropometrical measurements of obesity; BMI which is a good marker of WAT. Furthermore, we observed an association between IL-1β, sE-selectin and MCP-1, suggesting that the inflammatory atherosclerotic process is more severe in T2DM patients with CHD than in T2DM participants without CHD. Since circulating levels of sE-selectin reflect structural and functional changes of the vessel wall, it is tempting to speculate whether inflammation, manifested by dyslipidemia, increased inflammatory markers, namely hsCRP, IL-1β, and MCP-1, are involved in such changes.</p>
<p>In vulnerable patients, arteriosclerosis develops through the influence of stress conditions to the endothelium, such as aging (hence all groups were age matched), systemic arterial high blood pressure, hypercholesterolemia, T2DM, tobacco (hence excluded), and obesity itself. These factors damage the endothelium and initiate/enhance an inflammatory/proliferative reaction on the vascular wall. In turn, this increases the secretion of primary proinflammatory cytokines, such as IL-1. These are responsible for the expression of the endothelial adhesion molecule sE-selectins and the increase in the chemotactic protein MCP-1, an amplifier of the inflammatory cascade.<sup><xref ref-type="bibr" rid="bibr33-0003319711408587">33</xref></sup> These observations are consistent with the hypothesis that MCP-1 contributes both to recruiting macro phages to adipose tissue and development of IR. Thus, MCP-1 links obesity and IR through the induction of an inflammatory response in adipose tissues.<sup><xref ref-type="bibr" rid="bibr34-0003319711408587">34</xref></sup></p>
<p>A widely accepted theory states that IR is the primary abnormality that gives rise to T2DM, HTN, and dyslipidemia and that endothelial dysfunction merely represents the impact of hyperglycemia and other features of the MetS.<sup><xref ref-type="bibr" rid="bibr25-0003319711408587">25</xref></sup> However, an alternative concept emerged placing endothelial dysfunction at the core of MetS, which is well demonstrated in this study.</p>
<p>Obesity-induced IR could be explained by different mechanisms such as a decrease in insulin-sensitizing adipokines (eg, adiponectin).<sup><xref ref-type="bibr" rid="bibr35-0003319711408587">35</xref></sup> Adiponectin plays a role in obesity-related IR as its production and concentration decreases in obesity.<sup><xref ref-type="bibr" rid="bibr36-0003319711408587">36</xref></sup> Another explanation<sup><xref ref-type="bibr" rid="bibr37-0003319711408587">37</xref></sup> is that obesity-induced IR is aggravated by inflammatory mechanisms, as obesity is characterized by macrophage accumulation in WAT, which may contribute to a reduction in insulin-sensitizing adipokines. A third explanation<sup><xref ref-type="bibr" rid="bibr38-0003319711408587">38</xref></sup> is that the obesity-related elevation of fatty acids causes oxidative stress, a causative factor in the development of IR. Moreover, E-selectin expression is relatively low in normal vascular cells and is upregulated in response to various stimuli, including cytokines and/or oxidants, thus enabling monocytes to adhere to the vessel wall.<sup><xref ref-type="bibr" rid="bibr39-0003319711408587">39</xref></sup> Elevated levels of sE-selectin represent an early marker of several pathogenic processes associated with endothelial dysfunction and development of CHD and T2DM.<sup><xref ref-type="bibr" rid="bibr40-0003319711408587">40</xref></sup>
</p>
<p>As surrogate markers for insulin sensitivity and glucose metabolism as well as for early endothelial damage and activation, adiponectin and sE-selectin, respectively, were significantly and negatively correlated. The strength of our conclusions is limited by the small number of patients studied.</p>
<p>Various treatments, such as insulin, oral hypoglycemic, antihypertensive, hypolipidemic, antiobesity and antiplatelet drugs, which may be used in obese patients with or without T2DM may influence the levels of adipokine in patients with T2DM.<sup><xref ref-type="bibr" rid="bibr6-0003319711408587">6</xref></sup> The clinical relevance of these effects needs to be evaluated. Moreover, normalization of adipokine levels might confer an additional clinical benefit in the effort to prevent or treat obesity-related T2DM with MetS and CVD.<sup><xref ref-type="bibr" rid="bibr3-0003319711408587">3</xref>,<xref ref-type="bibr" rid="bibr6-0003319711408587">6</xref>,<xref ref-type="bibr" rid="bibr41-0003319711408587">41</xref></sup></p>
<p>In conclusion, in obese nonsmoker diabetic male patients hyperglycemia, dyslipidemia, hyperinsulinemia, oxidative stress, and endothelial activation, as surrogate markers of inflammation, are elevated and significantly associated with hypoadiponectinemia. These findings support the view that WAT plays a role, together with increased oxidative stress, proinflammatory markers and endothelial adhesion molecules, in the pathogenesis of CHD in obese T2DM patients.</p>
</sec>
</body>
<back>
<ack>
<title>Acknowledgment</title>
<p>The authors would like to thank the medical staff at Ain Shams University Specialized Hospitals (ASUSH) for providing samples.</p>
</ack>
<fn-group>
<fn fn-type="other" id="fn1-0003319711408587">
<p>HOE defined concepts, design, carried out data acquisition, data analysis, and manuscript review. NMH participated in sample design, collection, sample analysis, data acquisition, data analysis, statistical analysis, manuscript preparation, editing, and review. TMS shared in data analysis. SMI collected samples, performed sample analysis, manuscript preparation, and editing. The study was approved by the Committee on Medical Ethics of ASUSH. The study was carried out in accordance with the regulations and recommendations of the Declaration of Helsinki (REC number: GH2008H).</p>
</fn>
<fn fn-type="conflict" id="fn2-0003319711408587">
<p>The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.</p>
</fn>
<fn fn-type="financial-disclosure" id="fn3-0003319711408587">
<p>The author(s) received no financial support for the research, authorship, and/or publication of this article.</p>
</fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="bibr1-0003319711408587">
<label>1</label>
<citation citation-type="book">
<collab collab-type="author">The World Health Organization</collab>. <source>Cardiovascular Disease Prevention and Control Fact Sheet, 2007</source>. <publisher-loc>Geneva, Switzerland</publisher-loc>: <publisher-name>World Health Organization</publisher-name>; <year>2007</year>,<fpage>317</fpage>–<lpage>327</lpage>.</citation>
</ref>
<ref id="bibr2-0003319711408587">
<label>2</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Qasim</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Mehta</surname>
<given-names>NN</given-names>
</name>
<name>
<surname>Mahet</surname>
<given-names>G</given-names>
</name>
<etal/>
</person-group>. <article-title>Adipokines, insulin resistance, and coronary artery calcification</article-title>. <source>J Am Coll Cardiol</source>. <year>2008</year>;<volume>52</volume>(<issue>3</issue>):<fpage>231</fpage>–<lpage>236</lpage>.</citation>
</ref>
<ref id="bibr3-0003319711408587">
<label>3</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Athyros</surname>
<given-names>VG</given-names>
</name>
<name>
<surname>Tziomalos</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Karagiannis</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Mikhailidis</surname>
<given-names>DP.</given-names>
</name>
</person-group> <article-title>Dyslipidaemia of obesity, metabolic syndrome and type 2 diabetes mellitus: the case for residual risk reduction after statin treatment</article-title>. <source>Open Cardiovasc Med J</source>. <year>2011</year>;<volume>5</volume>:<fpage>24</fpage>–<lpage>34</lpage>. <comment>DOI: 10.2174/1874192401105010024</comment>.</citation>
</ref>
<ref id="bibr4-0003319711408587">
<label>4</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Austin</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>King</surname>
<given-names>MC</given-names>
</name>
<name>
<surname>Vranizan</surname>
<given-names>KM</given-names>
</name>
<name>
<surname>Krauss</surname>
<given-names>RM.</given-names>
</name>
</person-group> <article-title>Atherogenic lipoprotein phenotype: a proposed genetic marker for coronary heart disease risk</article-title>. <source>Circulation</source>. <year>2010</year>;<volume>82</volume>(<issue>2</issue>):<fpage>495</fpage>–<lpage>506</lpage>.</citation>
</ref>
<ref id="bibr5-0003319711408587">
<label>5</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wannamethee</surname>
<given-names>SG</given-names>
</name>
<name>
<surname>Tchernova</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Whincup</surname>
<given-names>P</given-names>
</name>
<etal/>
</person-group>. <article-title>Associations of adiponectin with metabolic and vascular risk parameters in the British Regional Heart Study reveal stronger links to insulin resistance-related than to coronary heart disease risk-related parameters</article-title>. <source>Int J Obes</source>. <year>2007</year>;<volume>31</volume>(<issue>7</issue>):<fpage>1089</fpage>–<lpage>1098</lpage>.</citation>
</ref>
<ref id="bibr6-0003319711408587">
<label>6</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Katsiki</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Mikhailidis</surname>
<given-names>DP</given-names>
</name>
<name>
<surname>Gotzamani-Psarrakou</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Yovos</surname>
<given-names>JG</given-names>
</name>
<name>
<surname>Karamitsos</surname>
<given-names>D.</given-names>
</name>
</person-group> <article-title>Effect of various treatments on leptin, adiponectin, ghrelin and neuropeptide Y in patients with type 2 diabetes mellitus</article-title>. <source>Expert Opin Ther Targets</source>. <year>2011</year>;<volume>15</volume>(<issue>4</issue>):<fpage>401</fpage>–<lpage>420</lpage>.</citation>
</ref>
<ref id="bibr7-0003319711408587">
<label>7</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kumada</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Kihara</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Sumitsuji</surname>
<given-names>S</given-names>
</name>
<etal/>
</person-group>. <article-title>Association of hypoadiponectinemia with coronary artery disease in men</article-title>. <source>Arterioscler Thromb Vasc Biol</source>. <year>2003</year>;<volume>23</volume>(<issue>1</issue>):<fpage>85</fpage>–<lpage>89</lpage>.</citation>
</ref>
<ref id="bibr8-0003319711408587">
<label>8</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Adamczak</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Więcek</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Funahashi</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Chudek</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Kokot</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Matsuzawa</surname>
<given-names>Y.</given-names>
</name>
</person-group> <article-title>Decreased plasma adiponectin concentrations in patients with essential hypertension</article-title>. <source>Am J Hypertens</source>. <year>2003</year>;<volume>16</volume>(<issue>1</issue>):<fpage>72</fpage>–<lpage>75</lpage>.</citation>
</ref>
<ref id="bibr9-0003319711408587">
<label>9</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Okamoto</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Kihara</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Ouchi</surname>
<given-names>N</given-names>
</name>
<etal/>
</person-group>. <article-title>Adiponectin reduces atherosclerosis in apolipoprotein E-deficient mice</article-title>. <source>Circulation</source>. <year>2002</year>;<volume>106</volume>(<issue>22</issue>):<fpage>2767</fpage>–<lpage>2770</lpage>.</citation>
</ref>
<ref id="bibr10-0003319711408587">
<label>10</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Herlitz</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Malmberg</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Karlson</surname>
<given-names>BW</given-names>
</name>
<name>
<surname>Ryden</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Hjalmarson</surname>
<given-names>A.</given-names>
</name>
</person-group> <article-title>Mortality and morbidity during a five-year follow up of diabetics with myocardial infarction</article-title>. <source>Acta Med Scand</source>. <year>1988</year>;<volume>224</volume>(<issue>1</issue>):<fpage>31</fpage>–<lpage>38</lpage>.</citation>
</ref>
<ref id="bibr11-0003319711408587">
<label>11</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Haffner</surname>
<given-names>SM</given-names>
</name>
<name>
<surname>Lehto</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Ronnemaa</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Pyorala</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Laakso</surname>
<given-names>M.</given-names>
</name>
</person-group> <article-title>Mortality from coronary heart disease in subjects with type 2 diabetes and in non diabetic subjects with and without prior myocardial infarction</article-title>. <source>N Engl J Med</source>. <year>1998</year>;<volume>339</volume>(<issue>4</issue>):<fpage>229</fpage>–<lpage>234</lpage>.</citation>
</ref>
<ref id="bibr12-0003319711408587">
<label>12</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>El-Mesallamy</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Suwailem</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Hamdy</surname>
<given-names>N.</given-names>
</name>
</person-group> <article-title>Evaluation of C - reactive protein, endothelin-1, adhesion molecule(s), and lipids as inflammatory markers in type 2 diabetes mellitus patients</article-title>. <source>Mediators Inflamm</source>. <year>2007</year>;<volume>2007</volume>:<fpage>73635</fpage>–<lpage>73642</lpage>.</citation>
</ref>
<ref id="bibr13-0003319711408587">
<label>13</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>El-Mesallamy</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Hamdy</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Suwailem</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Mostafa</surname>
<given-names>S.</given-names>
</name>
</person-group> <article-title>Oxidative stress and platelet activation: markers of myocardial infarction in type 2 diabetes mellitus</article-title>. <source>Angiology</source>. <year>2010</year>;<volume>61</volume>(<issue>1</issue>):<fpage>14</fpage>–<lpage>18</lpage>.</citation>
</ref>
<ref id="bibr14-0003319711408587">
<label>14</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Abraham</surname>
<given-names>EC</given-names>
</name>
<name>
<surname>Huff</surname>
<given-names>TA</given-names>
</name>
<name>
<surname>Cope</surname>
<given-names>ND</given-names>
</name>
<name>
<surname>Wilson</surname>
<given-names>JB</given-names>
<suffix>Jr</suffix>
</name>
<name>
<surname>Bransome</surname>
<given-names>ED</given-names>
<suffix>Jr</suffix>
</name>
<name>
<surname>Huisman</surname>
<given-names>TH.</given-names>
</name>
</person-group> <article-title>Determination of the glycosylated hemoglobins (HbA1) with a new microcolumn procedure. Suitability of the technique for assessing the clinical management of diabetes mellitus</article-title>. <source>Diabetes</source>. <year>1978</year>;<volume>27</volume>(<issue>9</issue>):<fpage>931</fpage>–<lpage>937</lpage>.</citation>
</ref>
<ref id="bibr15-0003319711408587">
<label>15</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Trinder</surname>
<given-names>P.</given-names>
</name>
</person-group> <article-title>Determination of blood glucose using an oxidase-peroxidase system with a non-carcinogenic chromogen</article-title>. <source>J Clin Pathol</source>. <year>1969</year>;<volume>22</volume>(<issue>2</issue>):<fpage>158</fpage>–<lpage>161</lpage>.</citation>
</ref>
<ref id="bibr16-0003319711408587">
<label>16</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Richmond</surname>
<given-names>W.</given-names>
</name>
</person-group> <article-title>Preparation and properties of a cholesterol oxidase from Nocardia sp. and its application to the enzymatic assay of total cholesterol in serum</article-title>. <source>Clin Chem</source>. <year>1973</year>;<volume>19</volume>(<issue>12</issue>):<fpage>1350</fpage>–<lpage>1356</lpage>.</citation>
</ref>
<ref id="bibr17-0003319711408587">
<label>17</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Siedel</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Hagele</surname>
<given-names>EO</given-names>
</name>
<name>
<surname>Ziegenhorn</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Wahlefeld</surname>
<given-names>AW.</given-names>
</name>
</person-group> <article-title>Reagent for the enzymatic determination of serum total cholesterol with improved lipolytic efficiency</article-title>. <source>Clin Chem</source>. <year>1983</year>;<volume>29</volume>(<issue>6</issue>):<fpage>1075</fpage>–<lpage>1080</lpage>.</citation>
</ref>
<ref id="bibr18-0003319711408587">
<label>18</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Burstein</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Scholnick</surname>
<given-names>HR</given-names>
</name>
<name>
<surname>Morfin</surname>
<given-names>R.</given-names>
</name>
</person-group> <article-title>Rapid method for the isolation of lipoproteins from human serum by precipitation with polyanions</article-title>. <source>J Lipid Res</source>. <year>1970</year>;<volume>11</volume>(<issue>6</issue>):<fpage>583</fpage>–<lpage>595</lpage>.</citation>
</ref>
<ref id="bibr19-0003319711408587">
<label>19</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hatch</surname>
<given-names>FT</given-names>
</name>
<name>
<surname>Lees</surname>
<given-names>RS.</given-names>
</name>
</person-group> <article-title>Practical methods for plasma lipoprotein analysis</article-title>. <source>Adv Lipid Res</source>. <year>1968</year>;<volume>6</volume>:<fpage>1</fpage>–<lpage>68</lpage>.</citation>
</ref>
<ref id="bibr20-0003319711408587">
<label>20</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Janero</surname>
<given-names>DR.</given-names>
</name>
</person-group> <article-title>Malondialdehyde and thiobarbituric acid-reactivity as diagnostic indices of lipid peroxidation and peroxidative tissue injury</article-title>. <source>Free Radical Biol Med</source>. <year>1990</year>;<volume>9</volume>(<issue>6</issue>):<fpage>515</fpage>–<lpage>540</lpage>.</citation>
</ref>
<ref id="bibr21-0003319711408587">
<label>21</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Matthews</surname>
<given-names>DR</given-names>
</name>
<name>
<surname>Hosker</surname>
<given-names>JP</given-names>
</name>
<name>
<surname>Rudenski</surname>
<given-names>AS</given-names>
</name>
<name>
<surname>Naylor</surname>
<given-names>BA</given-names>
</name>
<name>
<surname>Treacher</surname>
<given-names>DF</given-names>
</name>
<name>
<surname>Turner</surname>
<given-names>RC.</given-names>
</name>
</person-group> <article-title>Homeostasis model assessment: insulin resistance and b cell function from fasting plasma glucose and insulin concentration in man</article-title>. <source>Diabetologia</source>. <year>1985</year>;<volume>28</volume>(<issue>7</issue>):<fpage>412</fpage>–<lpage>419</lpage>.</citation>
</ref>
<ref id="bibr22-0003319711408587">
<label>22</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Green</surname>
<given-names>LC</given-names>
</name>
<name>
<surname>Wagner</surname>
<given-names>DA</given-names>
</name>
<name>
<surname>Glogowski</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Skipper</surname>
<given-names>PL</given-names>
</name>
<name>
<surname>Wishnok</surname>
<given-names>JS</given-names>
</name>
<name>
<surname>Tannenbaum</surname>
<given-names>SR.</given-names>
</name>
</person-group> <article-title>Analysis of nitrate, nitrite, and [15N] nitrate in biological fluids</article-title>. <source>Analyt Biochem</source>. <year>1982</year>;<volume>126</volume>(<issue>1</issue>):<fpage>131</fpage>–<lpage>138</lpage>.</citation>
</ref>
<ref id="bibr23-0003319711408587">
<label>23</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Alhusseini</surname>
<given-names>NF</given-names>
</name>
<name>
<surname>Belacy</surname>
<given-names>NA</given-names>
</name>
<name>
<surname>Kasem</surname>
<given-names>EM</given-names>
</name>
<name>
<surname>Allam</surname>
<given-names>MM.</given-names>
</name>
</person-group> <article-title>Effect of exercise training on adiponectin receptor expression and insulin resistance in mice fed a high fat diet</article-title>. <source>Am J Biochem Biotechnol</source>. <year>2010</year>;<volume>6</volume>(<issue>2</issue>):<fpage>77</fpage>–<lpage>83</lpage>.</citation>
</ref>
<ref id="bibr24-0003319711408587">
<label>24</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Qasim</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Mehta</surname>
<given-names>NN</given-names>
</name>
<name>
<surname>Mahet</surname>
<given-names>G.</given-names>
</name>
</person-group> <article-title>Adipokines, insulin resistence, and coronary artery calcification</article-title>. <source>J Am Coll Cardiol</source>. <year>2008</year>;<volume>52</volume>:<fpage>231</fpage>–<lpage>236</lpage>.</citation>
</ref>
<ref id="bibr25-0003319711408587">
<label>25</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schalkwijk</surname>
<given-names>CG</given-names>
</name>
<name>
<surname>Stehouwer</surname>
<given-names>CDA.</given-names>
</name>
</person-group> <article-title>Vascular complications in diabetes mellitus: the role of endothelial dysfunction</article-title>. <source>Clin Sci</source>. <year>2005</year>;<volume>109</volume>:<fpage>143</fpage>–<lpage>159</lpage>.</citation>
</ref>
<ref id="bibr26-0003319711408587">
<label>26</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Caballero</surname>
<given-names>AE.</given-names>
</name>
</person-group> <article-title>Endothelial dysfunction in obesity and insulin resistance: a road to diabetes and heart disease</article-title>. <source>Obes Res</source>. <year>2003</year>;<volume>11</volume>(<issue>11</issue>):<fpage>1278</fpage>–<lpage>1289</lpage>.</citation>
</ref>
<ref id="bibr27-0003319711408587">
<label>27</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fernandes</surname>
<given-names>JL</given-names>
</name>
<name>
<surname>Soeiro</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Ferreira</surname>
<given-names>CB</given-names>
</name>
<name>
<surname>Serrano</surname>
<given-names>CV.</given-names>
</name>
</person-group> <article-title>Síndromes coronárias agudas e inflamação</article-title>. <source>Rev Soc Cardiol Estado de São Paulo</source>. <year>2006</year>;<volume>3</volume>:<fpage>178</fpage>–<lpage>187</lpage>.</citation>
</ref>
<ref id="bibr28-0003319711408587">
<label>28</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Navarro</surname>
<given-names>JF</given-names>
</name>
<name>
<surname>Mora</surname>
<given-names>C.</given-names>
</name>
</person-group> <article-title>Role of inflammation in diabetic complications</article-title>. <source>Nephrol Dial Transplant</source>. <year>2005</year>;<volume>20</volume>(<issue>12</issue>):<fpage>2601</fpage>–<lpage>2604</lpage>.</citation>
</ref>
<ref id="bibr29-0003319711408587">
<label>29</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kawashima</surname>
<given-names>S.</given-names>
</name>
</person-group> <article-title>The two faces of endothelial nitric oxide synthase in the pathophysiology of atherosclerosis</article-title>. <source>Endothelium</source>. <year>2004</year>;<volume>11</volume>(<issue>2</issue>):<fpage>99</fpage>–<lpage>107</lpage>.</citation>
</ref>
<ref id="bibr30-0003319711408587">
<label>30</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kahn</surname>
<given-names>BB</given-names>
</name>
<name>
<surname>Flier</surname>
<given-names>JS.</given-names>
</name>
</person-group> <article-title>Obesity and insulin resistance</article-title>. <source>J Clin Invest</source>. <year>2001</year>;<volume>106</volume>:<fpage>473</fpage>–<lpage>481</lpage>.</citation>
</ref>
<ref id="bibr31-0003319711408587">
<label>31</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sartipy</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Loskutoff</surname>
<given-names>DJ.</given-names>
</name>
</person-group> <article-title>Monocyte chemoattractant protein 1 in obesity and insulin resistance</article-title>. <source>Proc Natl Acad Sci USA</source>. <year>2003</year>;<volume>100</volume>(<issue>12</issue>):<fpage>7265</fpage>–<lpage>7270</lpage>.</citation>
</ref>
<ref id="bibr32-0003319711408587">
<label>32</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jung</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Gerdes</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Fritzenwanger</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Figulla</surname>
<given-names>HR.</given-names>
</name>
</person-group> <article-title>Circulating levels of interleukin-1 family cytokines in overweight adolescents</article-title>. <source>Mediators Inflamm</source>. <year>2010</year>; <comment>2010.doi:10.1155/2010/958403</comment>
</citation>
</ref>
<ref id="bibr33-0003319711408587">
<label>33</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gomes</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Telo</surname>
<given-names>DF</given-names>
</name>
<name>
<surname>Souza</surname>
<given-names>HP</given-names>
</name>
<name>
<surname>Nicolau</surname>
<given-names>JC</given-names>
</name>
<name>
<surname>Halpern</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Serrano</surname>
<given-names>CV</given-names>
<suffix>Jr</suffix>
</name>
</person-group>. <article-title>Obesity and coronary artery disease: role of vascular inflammation</article-title>. <source>Arq Bras Cardiol</source>. <year>2010</year>;<volume>94</volume>(<issue>2</issue>):<fpage>273</fpage>–<lpage>279</lpage>. <comment>doi: 10.1590/S0066-782X2010000200021</comment>
</citation>
</ref>
<ref id="bibr34-0003319711408587">
<label>34</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bruun</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Lihn</surname>
<given-names>AS</given-names>
</name>
<name>
<surname>Pedersen</surname>
<given-names>SB</given-names>
</name>
<name>
<surname>Richelsen</surname>
<given-names>B.</given-names>
</name>
</person-group> <article-title>Monocyte chemoattractant protein-1 release is higher in visceral than subcutaneous human adipose tissue (AT): implication of macrophages resident in the AT</article-title>. <source>J Clin Endocrinol Metab</source>. <year>2005</year>;<volume>90</volume>(<issue>4</issue>):<fpage>2282</fpage>–<lpage>2289</lpage>.</citation>
</ref>
<ref id="bibr35-0003319711408587">
<label>35</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Diez</surname>
<given-names>JJ</given-names>
</name>
<name>
<surname>Iglesias</surname>
<given-names>P.</given-names>
</name>
</person-group> <article-title>The role of the novel adipocyte-derived hormone adiponectin in human disease</article-title>. <source>Eur J Endocrinol</source>. <year>2003</year>;<volume>148</volume>(<issue>3</issue>):<fpage>293</fpage>–<lpage>300</lpage>.</citation>
</ref>
<ref id="bibr36-0003319711408587">
<label>36</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tsao</surname>
<given-names>TS</given-names>
</name>
<name>
<surname>Lodish</surname>
<given-names>HF</given-names>
</name>
<name>
<surname>Fruebis</surname>
<given-names>J.</given-names>
</name>
</person-group> <article-title>Acrp 30, a new hormone controlling fat and glucose metabolism</article-title>. <source>Eur J Pharmacol</source>. <year>2002</year>;<volume>440</volume>(<issue>2-3</issue>):<fpage>213</fpage>–<lpage>221</lpage>.</citation>
</ref>
<ref id="bibr37-0003319711408587">
<label>37</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lumeng</surname>
<given-names>CN</given-names>
</name>
<name>
<surname>Bodzin</surname>
<given-names>JL</given-names>
</name>
<name>
<surname>Saltiel</surname>
<given-names>AR.</given-names>
</name>
</person-group> <article-title>Obesity induces a phenotypic switch in adipose tissue macrophage polarization</article-title>. <source>J. Clin. Invest</source>. <year>2007</year>;<volume>117</volume>(<issue>1</issue>):<fpage>175</fpage>–<lpage>184</lpage>.</citation>
</ref>
<ref id="bibr38-0003319711408587">
<label>38</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Houstis</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Rosen</surname>
<given-names>ED</given-names>
</name>
<name>
<surname>Lander</surname>
<given-names>ES.</given-names>
</name>
</person-group> <article-title>Reactive oxygen species have a causal role in multiple forms of insulin resistance</article-title>. <source>Nature</source>. <year>2006</year>;<volume>440</volume>(<issue>7086</issue>):<fpage>944</fpage>–<lpage>948</lpage>.</citation>
</ref>
<ref id="bibr39-0003319711408587">
<label>39</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mulvihill</surname>
<given-names>NT</given-names>
</name>
<name>
<surname>Foley</surname>
<given-names>JB</given-names>
</name>
<name>
<surname>Crean</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Walsh</surname>
<given-names>M.</given-names>
</name>
</person-group> <article-title>Prediction of cardiovascular risk using soluble cell adhesion molecules</article-title>. <source>Eur Heart J</source>. <year>2002</year>;<volume>23</volume>(<issue>20</issue>):<fpage>1569</fpage>–<lpage>1574</lpage>.</citation>
</ref>
<ref id="bibr40-0003319711408587">
<label>40</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Halcox</surname>
<given-names>JP</given-names>
</name>
<name>
<surname>Schenke</surname>
<given-names>WH</given-names>
</name>
<name>
<surname>Zalos</surname>
<given-names>G</given-names>
</name>
<etal/>
</person-group>. <article-title>Prognostic value of coronary vascular endothelial dysfunction</article-title>. <source>Circulation</source>. <year>2002</year>;<volume>106</volume>(<issue>6</issue>):<fpage>653</fpage>–<lpage>658</lpage>.</citation>
</ref>
<ref id="bibr41-0003319711408587">
<label>41</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Athyros</surname>
<given-names>VG</given-names>
</name>
<name>
<surname>Tziomalos</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Karagiannis</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Anagnostis</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Mikhailidis</surname>
<given-names>DP.</given-names>
</name>
</person-group> <article-title>Should adipokines be considered in the choice of the treatment of obesity-related health problems?</article-title> <source>Curr Drug Targets</source>. <year>2010</year>;<volume>11</volume>(<issue>1</issue>):<fpage>122</fpage>–<lpage>135</lpage>.</citation>
</ref>
</ref-list>
</back>
</article>